How to devise safety and immunotoxicity assessments for Antibodies

immunotoxicity, genmab,

Are you looking to improve your understanding of how your antibodies bind, and how and where glycosylation is taking place?

Dr Jeroen Lammerts van Bueren a Senior Scientist at GenMab recently presented data suggesting where therapeutic mAbs are glycosylated and also what the effect of producing in rodent cell lines is in terms of binding:


Investigating the binding of IgE anti-gal-1.3 alpha-gal antibodies from allergic patients to a panel of therapeutic antibodies

  • Non-human a-Gal glycan structures on therapeutic antibodies.
  • The interaction between IgE against a-Gal and antibody therapeutics
  • Underlying mechanisms

Click here for the full presentation


Do you want to find out more?

How to take an antibody from academic discovery to the patient

How to define acceptable changes for QA's of antibodies

Strategies to enhance #antibody efficacy


For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *